OUR EPIGENETIC SOLUTION HAS SEVERAL ADVANTAGES COMPARED TO TRADITIONAL GENETIC TOOLS


  • uniquely high accuracy and quality control
  • low amount of input DNA
  • high sensitivity and specificity, even at low sequence depth
  • bisulfite-free method avoiding the loss of critical information
  • challenges the overcome limitations of the current analytical standards
  • scalability to multiple scopes and cancer types
  • wet lab technique can be performed locally using existing infrastructure
  • performing the wet lab technique only requires standard equipment
  • results within short timeframe at reasonable costs
  • robust analytical power for demonstrations of drug and therapeutic efficacy
  • can be used as the foundation of personalized cancer diagnosis and treatment strategies
  • potential in other diseases than cancer

METHYLEX VALUE-ADD IS SCALABLE AT MULTIPLE LEVELS


Methylex method helps to evaluate methylation complexity with upscaled classification accuracy.

Epigenome-wide mapping of DNA methylation related information can be reached without investing in costly ICT infrastructure.

Bigdata-driven setting performs efficient one-time instance tailoring on large datasets for various research scopes.

We provide an advanced depth of molecular epigenetic analysis.

We have identified a new potential of disease profiling by reading and analyzing at least ten times more data than the recent standards on the market.

Methylex technique is flexibly adoptable as a uniquely precise detection and localization technique for laboratory medicine practices.

DNA methylation related epigenetic alterations (ep-mutations) proved us specific signals conserved across individuals and among clinical groups.

Methylex workflow can be used as a powerful verification tool of drug response.

Our analysis of epigenetic modifications has a higher sensitivity and stability compared with the recently applied techniques.

Identification of methylation patterns are built up from billions of epigenetic data.

Methylex technology is a leading-edge approach includes a possible game-changing accuracy in disease-specific information.

Our bigdata-driven tool works with flexibly scalable analytical model during the clinical evaluation of such therapeutic products.

METHYLEX SOLUTION HAS A GREAT POTENTIAL IN THE TREATMENT OF DISEASES OTHER THAN CANCER


Our technique could be used to diagnose and predict the outcome or monitor the development of more human diseases resulting a higher probability of a successful treatment of the patients. We are continuously developing our solution to extend its advantages in the near future, especially in the following fields.

Prenatal disorders

Share Your thoughts

Organ transplantation

Share Your thoughts

Autoimmune diseases

Share Your thoughts

Heart problems

Share Your thoughts

Infectious diseases

Share Your thoughts

FOR CANCER RESEARCH ORGANIZATIONS


We are offering flexible on-site services covering the molecular epigenetic data collection and bioinformatic preprocessing. Our workflow mitigates quality-control risks where the sequencing steps need input datasets in a very high-quality. Methylex solution supports researches on customers facilities. Computational analysis can be ordered as an additional service or performed in a collaborative manner.

Contact us

FOR HEALTHCARE UNITS OF ONCOLOGY


Epigenetic data-driven health services unlock the potential of early detection and monitoring of diseases. We are currently working on Methylex diagnostic labels to provide affordable and easy-accessible medical tests at a wide range for the global society. We are also opened to cooperate with public- or private healthcare units to design their own DNA-methylation related laboratory settings in various medical fields.

Contact us

FOR PHARMA COMPANIES


Methylex analysis from raw files establishes powerful analytical tool where reports are tailored to customer requirements. Our solution unlocks sufficient sensitivity of drug response specific information. Reports are based on a possibly game-changing depth of clinical evidence. Robust demonstrations can be achieved within a short timeframe at reasonable costs.

Contact us

FOR INDUSTRIAL CUSTOMERS


Methylex is providing exceptionally accurate demonstration of the onco-therapeutic response of particular patient clusters. We utilize DNA methylation-driven epigenetic marks to return invaluable information for our customers during the clinical evaluation of their onco-therapeutic products.

Contact us